CanBas Co (4575.T) Stock Price

CanBas Co Price

CLOSED
764.00
​
Market closed

Revenue at CanBas Co has contracted by 0.3% per year over the past 15 years to 53.48 M JPY. For CanBas Co, the net margin of -1,599.8% is down versus -483.7% a few years ago.

CanBas Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CanBas Co business model & stock analysis

CanBas Co Ltd is a biotechnology company based in Numazu-shi, Japan, operating within the healthcare sector. The company has a small team of 12 employees and went public on September 17, 2009, with its ticker listed as 4575.T and ISIN JP3244570002. Its primary focus is on anticancer drug discovery research, which includes developing drug discovery concepts, selecting candidate compounds through method-based approaches, conducting simple animal studies, and analyzing basic data on anticancer drug candidates entering development. Additionally, CanBas engages in early clinical development activities, such as preclinical studies required before submitting applications for clinical trials and conducting the initial phases of clinical trials. The company maintains a website at https://www.canbas.co.jp/ for further information. CanBas operates as a private entity with a minimal workforce, emphasizing research and development in the early stages of anticancer drug development. It does not provide details on specific products, acquisitions, or financial figures beyond its IPO date and employee count. The company's headquarters are located in Numazu-shi, Shizuoka Prefecture, Japan, and it is listed on the Tokyo Stock Exchange. Its operations are centered around foundational research in oncology, aiming to contribute to the discovery and development of new anticancer treatments.

Frequently asked questions about CanBas Co

Converted at the current exchange rate, the CanBas Co share trades at 4.30 EUR (764.00 JPY).

The revenue cannot currently be calculated for CanBas Co.

The profit of CanBas Co is -1.31 B JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of CanBas Co is currently -11.50. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the CanBas Co stock.

The P/S cannot be calculated for CanBas Co currently.

The Eulerpool Quality Score for CanBas Co is 2/10.

The ISIN of CanBas Co is JP3244570002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of CanBas Co is 4575.T. The ticker symbol is used to trade CanBas Co shares on the stock exchange.

Fair ValueTerminal
634.12 JPY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website canbas.co.jp
Country
Currency
JPY
Initial public offering
Sep 17, 2009
ISIN
JP3244570002
Cusip
J05251103
Market capitalization
15.06 B JPYLarge Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2027
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
9.17
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-79.71 %
Last updated Oct 18, 2026, 11:07 PM

CanBas Co Peer Group

CanBas Co FIGI

4575:JP · BBG000NXL0H94575:JT · BBG000NXL0Z94575:JJ · BBG000NXL5Z84575:JE · BBG000NXL6J44575:JI · BBG000NXL7934575:JU · BBG002QKH6J04575:JW · BBG00875K4664575:JV · BBG0193RCCN1

All fundamentals and in-depth analysis of CanBas Co

Our stock analysis for CanBas Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CanBas Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.